Farydak (panobinostat) / Secura Bio 
Welcome,         Profile    Billing    Logout  

12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
NCT02386800 / 2014-003527-22: CINC424A2X01B Rollover Protocol

Recruiting
4
356
Europe, Japan, RoW
ruxolitinib, INC424, Jakavi, panobinostat, LBH589, Farydak
Novartis Pharmaceuticals
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
09/27
09/27
2017-000764-15: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS

Ongoing
3
350
Europe
Farydak, Capsule, hard, Farydak
Universitätsklinikum Frankfurt, Novartis Pharma GmbH
High risk acute myeloid leukemia or myelodysplastic syndrome Hoch-risiko akute myeloische Leukämie oder myelodysplastisches Syndrom, Acute myeloid leukemia (AML). Myelodysplastic syndrome (MDS) Akute myeloische Leukämie (AML). Myelodysplastisches Syndrom (MDS)., Diseases [C] - Cancer [C04]
 
 
PANORAMA_3, NCT02654990 / 2015-001564-19: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed
2
249
Europe, Canada, US, RoW
panobinostat capsules, PAN, LBH589, bortezomib injection, BTZ, dexamethasone tablets, Dex
pharmaand GmbH, Novartis Pharma Services AG, Secura Bio, Inc.
Multiple Myeloma
10/19
08/22
2020-000382-16: Efficacy of daratumumab (Dara) retreatment of relapsed/ refractory multiple myeloma (RRMM) patients in combination with panobinostat, bortezomib-and dexamethasone Wirksamkeit einer wiederholten Daratumumab (Dara) Behandlung von Patienten mit rezidiviertem/refraktärem Multiplen Myelom (RRMM) in Kombination mit Panobinostat, Bortezomib und Dexamethason

Not yet recruiting
2
30
Europe
Darzalex, Farydak, Velcade, L01XC24, L01XX42, L01XX32, Concentrate for solution for injection, Capsule, hard, Powder for solution for injection, Daratumumab (DARZALEX® 1.800 mg Injektionslösung), Farydak (Panobinostat), Velcade (Bortezomib)
Medical Center - University of Freiburg, University of Freiburg, Faculty of Medicine, Janssen-Cilag GmbH
Relapsed and refractory multiple myeloma Rezidives und refraktäres Multiples Myelom, Relapsed and refractory multiple myeloma wiederkehrendes / therapieresistentes Multiples Myelom, Diseases [C] - Cancer [C04]
 
 
2012-003344-74: A study to evaluate the efficacy and safety of combination chemotherapy of panobinostat and decitabine, given after donor stem cell transplantation in patients with (very) poor risk AML

Ongoing
1/2
70
Europe
panobinostat, Dacogen, Dacogen
HOVON Foundation, Dutch Cancer Society, Novartis, Janssen Cilag, HOVON Foundation
(very) poor risk AML or RAEB with IPSS ≥ 1.5
 
 
2017-002335-42: A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation . Onderzoek naar de behandeling van patiënten met een specifiek type AML, met de middelen panobinstat en midostaurin gedurende 1 jaar na donor-stamceltransplantatie.

Ongoing
1/2
40
Europe
panobinostat, Midostaurin, Capsule, Farydak 20 mg, Rydapt
HOVON Foundation, Novartis
adverse risk AML or RAEB, 'High risk' acute myeloid leukemia of myedysplastic syndrome, Diseases [C] - Cancer [C04]
 
 
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed
1/2
17
US
Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys
Massachusetts General Hospital, Novartis, Genentech, Inc.
HIV Infection
08/22
12/23
DIPG, NCT04341311: Phase I Study of Marizomib + Panobinostat for Children With

Terminated
1
4
US
Marizomib, salinosporamide A, salinosporin A, Panobinostat, Farydak
Dana-Farber Cancer Institute, Celgene, Secura Bio, Inc.
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
02/24
02/24
NCT01245179: Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Recruiting
1
18
US
panobinostat, LBH589, LBH589 lactate, FARYDAK®
Abdullah Kutlar, Secura Bio, Inc.
Sickle Cell Disease
12/25
03/26
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No Longer Available
N/A
US
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
 
 
NCT02568943 / 2014-003239-21: An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

No Longer Available
N/A
Europe, Canada, RoW
Panobinostat, LBH589
Novartis Pharmaceuticals
Multiple Myeloma
 
 
RECOMM, NCT04150289: A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

Completed
N/A
248
US
Farydak
zr Pharma & GmbH
Multiple Myeloma
03/22
03/22

Download Options